Registration Now Open – 2016 Chabner Colloquium, November 11-12, 2016 in Boston, MA

Registration is now open for the Society for Translational Oncology (STO) Chabner Colloquium: Answering the Big Questions in Cancer Research & 2016 STO Annual Meeting.

Durham, NC (PRWEB) July 07, 2016 -- Registration is now open for the Society for Translational Oncology (STO) Chabner Colloquium: Answering the Big Questions in Cancer Research & 2016 STO Annual Meeting. This live symposium is jointly provided by the Massachusetts General Hospital Cancer Center and STO, in partnership with The Oncologist, STO's official journal. It will be held November 11-12, 2016 at The Liberty Hotel in Boston, Massachusetts.

The 2016 Chabner Colloquium will provide updates on the most promising targets for the development of new cancer treatments. Physician-scientists, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to view the agenda and confirmed faculty and register online at http://bit.ly/chabner2016.

Offered for the sixth year, the 2016 Chabner Colloquium includes presentations on emerging molecular targets for cancer treatments—with a focus on potentially productive opportunities for collaboration between academia and industry. Physician-scientists from leading U.S. research centers will address work in progress in a broad variety of topics in cancer therapeutics. Invited speakers hail from renowned institutions such as the Massachusetts General Hospital Cancer Center, the Broad Institute of MIT, Harvard, the Dana-Farber Cancer Institute, and companies, Novartis, ADT Pharmaceuticals, Inc., and Gurnet Point Capital.

The meeting is named for Dr. Bruce A. Chabner, Allen Distinguished Investigator, Clinical Director, Emeritus at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr. Chabner designs and leads this annual program. Dr. Chabner states, "It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead."

On Friday, November 11th, the session topics include lectures on new insights into cancer drug resistance, targets that defy effective therapy, and hematologic malignancies.

The day concludes with a forum of fellows from Massachusetts General Hospital Cancer Center, the Broad Institute of MIT, and Dana-Farber Cancer Institute sharing their recent work.

On Saturday, November 12th, the session topics include lectures on financing start-ups and neo-antigens and the immune response

STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This live activity is non-accredited, and CME credit will not be offered.

For more information contact STO at (919) 433-0489 or CMEadmin(at)sto-online(dot)org.

# # #
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: www.sto-online.org.

About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its twenty-first year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: www.theoncologist.com.

About the Massachusetts General Hospital Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.

U.S. News & World Report consistently ranks the Mass General Cancer Center as one of the top ten cancer centers in the country. Its nurses were the first in Massachusetts to achieve Magnet status from the American Nurses Credentialing Center in recognition of the hospital's exceptional nursing care.

Known for providing customized, innovative treatments and compassionate care to both adults and children, the Cancer Center comprises more than 37 treatment programs within 29 fully integrated, multidisciplinary disease centers and a vast array of support and educational services. Its network of affiliations extends throughout New England and the southeastern U.S.

The Cancer Center's commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.

The Massachusetts General Hospital Cancer Center is proud to be a founding member of a Harvard Medical School consortium designated by the National Cancer Institute as a comprehensive cancer center. This prestigious seven-member center forms the largest cancer research collaboration in the country. The promising new treatments developed through this partnership are revolutionizing the future of cancer medicine.

For more information, contact:
Jen Homan, Program Manager, STO
(919) 433-0489
jen.homan(at)sto-online(dot)org
Contact Information

Jen Homan
Society for Translational Oncology
+1 (919) 680-0011

Online Web 2.0 Version
You can read the online version of this press release here.